Pharmaceutical company Shire said it has bought New York-based Foresight Biotherapeutics Inc for $300 million in cash, gaining access to a late-stage therapy being developed for the treatment of conjunctivitis.
Shire, which formed an ophthalmics unit in May last year, is awaiting a decision by the Food and Drug Administration in the United states on its dry-eye disease treatment, lifitegrast. A decision is expected by October.
The company's acquisition of Foresight gives it access to the global rights to FST-100, which has showed promise in a mid-stage study.
Shire said it would conduct a phase-three trial for FST-100 to evaluate whether it could also be used to treat bacterial conjunctivitis.
The drug has the potential to become the first one to treat both viral and bacterial conjunctivitis, cutting the costs and risks associated with unnecessary antibiotic prescriptions for conjunctivitis, which is also known as pink eye.
It is highly transmissible and affects about 5.9 million people in the United States every year and about 5.4 million people across the European Union.
There is no therapy available to resolve the clinical signs and symptoms and to eradicate adenovirus, which is the most common cause of viral conjunctivitis.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here